

# Baris Gencer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6680615/baris-gencer-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

1,942  
citations

23  
h-index

42  
g-index

89  
ext. papers

2,622  
ext. citations

6  
avg, IF

4.94  
L-index

#	Paper	IF	Citations
80	Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. <i>Circulation</i> , <b>2012</b> , 126, 1040-9	16.7	315
79	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , <b>2018</b> , 39, 2526-2539	9.5	156
78	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , <b>2017</b> , 38, 2245-2255	9.5	105
77	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , <b>2015</b> , 36, 2438-45	9.5	91
76	Lipoprotein(a): the revenant. <i>European Heart Journal</i> , <b>2017</b> , 38, 1553-1560	9.5	89
75	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , <b>2016</b> , 37, 546-53	9.5	89
74	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , <b>2016</b> , 134, 698-709	16.7	79
73	Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. <i>European Heart Journal</i> , <b>2018</b> , 39, 503-507	9.5	67
72	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2020</b> , 396, 1637-1643	40	62
71	Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2452-2462	15.1	56
70	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2018</b> , 7, 129-138	4.3	52
69	Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2013</b> , 13, 4-12	2.2	44
68	Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. <i>Atherosclerosis</i> , <b>2016</b> , 245, 181-6	3.1	41
67	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , <b>2017</b> , 38, 3493-3502	9.5	33
66	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , <b>2020</b> , 141, 1600-1607	16.7	32
65	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 56-62	3.9	31
64	Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2283-2293	15.1	28

63	Ruling out coronary heart disease in primary care patients with chest pain: a clinical prediction score. <i>BMC Medicine</i> , <b>2010</b> , 8, 9	11.4	28
62	Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2988-2997	5.6	27
61	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. <i>Atherosclerosis</i> , <b>2015</b> , 239, 118-124	3.1	25
60	Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications. <i>PLoS ONE</i> , <b>2014</b> , 9, e93147	3.7	25
59	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. <i>European Heart Journal</i> , <b>2016</b> , 37, 3569-3575	9.5	23
58	Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 1017-24	4.6	23
57	Lipid management in ACS: Should we go lower faster?. <i>Atherosclerosis</i> , <b>2018</b> , 275, 368-375	3.1	23
56	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 952-957	16.2	22
55	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	21
54	The peak of blood lactate during the first 24h predicts mortality in acute coronary syndrome patients under extracorporeal membrane oxygenation. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 741-5	3.2	18
53	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1061-1073	27.4	16
52	A Randomized Study of SheathLess vs Standard Guiding Catheters for Transradial Percutaneous Coronary Interventions. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1425-1432	3.8	15
51	The Impact of Levothyroxine on Cardiac Function in Older Adults With Mild Subclinical Hypothyroidism: A Randomized Clinical Trial. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 848-856.e5	2.4	14
50	Identifying familial hypercholesterolemia in acute coronary syndrome. <i>Current Opinion in Lipidology</i> , <b>2016</b> , 27, 375-81	4.4	14
49	Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1513-1520	3.3	14
48	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195174	3.7	14
47	Inflammation during acute coronary syndromes - Risk of cardiovascular events and bleeding. <i>International Journal of Cardiology</i> , <b>2019</b> , 287, 13-18	3.2	12
46	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , <b>2019</b> , 49, e13117	4.6	12

45	PCSK9 inhibitors. <i>Swiss Medical Weekly</i> , <b>2015</b> , 145, w14094	3.1	12
44	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons. <i>BMJ Open</i> , <b>2016</b> , 6, e011520	3	12
43	Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2021</b> ,	16.7	12
42	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , <b>2018</b> , 277, 219-226	9.1	11
41	Association of electrocardiogram abnormalities and incident heart failure events. <i>American Heart Journal</i> , <b>2014</b> , 167, 869-75.e3	4.9	11
40	Low statin use in adults hospitalized with acute coronary syndrome. <i>Preventive Medicine</i> , <b>2015</b> , 77, 131-64	4.3	11
39	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. <i>Drugs</i> , <b>2020</b> , 80, 229-239	12.1	10
38	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 59-65	3.9	10
37	Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 257-274	10.5	10
36	Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161493	3.7	9
35	Health utility indexes in patients with acute coronary syndromes. <i>Open Heart</i> , <b>2016</b> , 3, e000419	3	9
34	The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study. <i>Journal of Health Psychology</i> , <b>2017</b> , 22, 208-217	3.1	8
33	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. <i>Atherosclerosis</i> , <b>2019</b> , 284, 253-259	3.1	7
32	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	7
31	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	7
30	Lipoprotein(a): the perpetual supporting actor. <i>European Heart Journal</i> , <b>2018</b> , 39, 2597-2599	9.5	6
29	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 9, 589-598	4.3	6
28	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , <b>2022</b> ,	16.7	5

27	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	5
26	Air pollution triggers inflammation and cardiovascular events: now is the time to act. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	5
25	So low to far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. <i>European Heart Journal</i> , <b>2018</b> , 39, 382-384	9.5	4
24	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , <b>2020</b> , 303, 8-13	3.2	4
23	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , <b>2016</b> , 18, 48	4.2	4
22	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
21	Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 684-690	3.3	3
20	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211464	3.7	2
19	Dynamical System Modeling of Self-Regulated Systems Undergoing Multiple Excitations: First Order Differential Equation Approach. <i>Multivariate Behavioral Research</i> , <b>2021</b> , 56, 649-668	2.3	2
18	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. <i>Swiss Medical Weekly</i> , <b>2016</b> , 146, w14275	3.1	2
17	Use and role of monoclonal antibodies and other biologics in preventive cardiology. <i>Swiss Medical Weekly</i> , <b>2015</b> , 145, w14179	3.1	2
16	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , <b>2020</b> , 13, 618-628	3.3	2
15	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2021</b> , 10, 855-865	4.3	2
14	Optimal Timing of Invasive Coronary Angiography following NSTEMI. <i>Journal of Interventional Cardiology</i> , <b>2020</b> , 2020, 8513257	1.8	1
13	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 35, 83-88	3.9	1
12	Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 795492	5.7	1
11	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 235-242	3.9	1
10	Emerging Concepts and Applied Machine Learning Research in Patients with Drug-Induced Repolarization Disorders. <i>Studies in Health Technology and Informatics</i> , <b>2020</b> , 270, 198-202	0.5	1

9	Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction-DOSE Finding Study) Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 61-61	4.9	1
8	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. <i>JACC: CardioOncology</i> , <b>2020</b> , 2, 385-396	3.8	0
7	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. <i>International Journal of Cardiology</i> , <b>2020</b> , 299, 289-295	3.2	0
6	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. <i>Atherosclerosis</i> , <b>2021</b> , 335, 77-83	3.1	0
5	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland.. <i>Preventive Medicine Reports</i> , <b>2021</b> , 24, 101583	2.6	
4	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. <i>Swiss Medical Weekly</i> , <b>2019</b> , 149, w20049	3.1	
3	New concepts in the management of dyslipidaemia. <i>Swiss Medical Weekly</i> , <b>2016</b> , 146, w14378	3.1	
2	Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with cardiovascular disease. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E446-50	2.6	
1	The Reply. <i>American Journal of Medicine</i> , <b>2021</b> , 134, e71	2.4	